A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
Public ClinicalTrials.gov record NCT06551142. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of Risvutatug rezetecan (Ris-Rez), also known as GSK5764227. The study will also see how the levels of Ris-Rez will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab, tarlatamab, dostarlimab
Study identification
- NCT ID
- NCT06551142
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 845 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Biological
- Bevacizumab Biological
- Carboplatin Drug
- Cetuximab Biological
- Cisplatin Drug
- Dostarlimab Biological
- Durvalumab Biological
- Pembrolizumab Biological
- Ris-Rez Biological
- Tarlatamab Biological
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2024
- Primary completion
- Oct 15, 2028
- Completion
- Jun 7, 2029
- Last update posted
- May 21, 2026
2024 – 2029
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Stanford | California | 94063 | Recruiting |
| GSK Investigational Site | Denver | Colorado | 80218 | Recruiting |
| GSK Investigational Site | New Haven | Connecticut | 06511 | Recruiting |
| GSK Investigational Site | Fort Wayne | Indiana | 46804 | Recruiting |
| GSK Investigational Site | Boston | Massachusetts | 02114 | Recruiting |
| GSK Investigational Site | Detroit | Michigan | 48201 | Recruiting |
| GSK Investigational Site | New Brunswick | New Jersey | 08903 | Recruiting |
| GSK Investigational Site | Myrtle Beach | South Carolina | 29572 | Recruiting |
| GSK Investigational Site | Nashville | Tennessee | 37203 | Recruiting |
| GSK Investigational Site | Austin | Texas | 78705 | Recruiting |
| GSK Investigational Site | Dallas | Texas | 75230 | Recruiting |
| GSK Investigational Site | San Antonio | Texas | 78229 | Recruiting |
| GSK Investigational Site | Tyler | Texas | 75702 | Recruiting |
| GSK Investigational Site | West Valley City | Utah | 84119 | Recruiting |
| GSK Investigational Site | Norfolk | Virginia | 23502 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.
Recently updated Neoplasms trials
Other public records listing Neoplasms. Sorted by last update posted; newest first. Not a recommendation.
- NCT07276373: Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies Recruiting
- NCT07038369: A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations Active, not recruiting
- NCT07715903: Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy Not yet recruiting
- NCT07438782: First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors Recruiting
- NCT03366116: 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors Recruiting
- NCT07382817: Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06551142, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 21, 2026 · Synced Jul 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06551142 live on ClinicalTrials.gov.